rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    NRXP
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      What NRx Pharmaceuticals (NRXP) Said on Its Q3 Earnings Call
      Nov 17Yahoo FinanceNRXP
      NRX Pharmaceuticals earnings beat by $0.18, revenue fell short of estimates
      Nov 17Investing.comNRXP
      NRx Pharmaceuticals, Inc. (NRXP) Reports Q3 Loss, Misses Revenue Estimates
      Nov 16Yahoo FinanceNRXP
      NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2026 Financial Results and Provide Corporate Update
      Nov 12Yahoo FinanceNRXP
      BTIG raises NRx Pharmaceuticals price target on sales force expansion
      Nov 12Investing.comNRXP
      Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday
      Nov 2BenzingaNRXPREGN
      NRx Pharmaceuticals Wins FDA Approval for Preservative-Free Ketamine Injection
      Oct 30Yahoo FinanceNRXP
      Why is NRX Pharmaceuticals stock surging today?
      Oct 30Investing.comNRXP
      12 Health Care Stocks Moving In Friday's Pre-Market Session
      Oct 30BenzingaINTSNRXP
      NRx Pharmaceuticals receives FDA approval for ketamine drug
      Oct 30Investing.comNRXP
      NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date
      Oct 30Yahoo FinanceNRXP
      NRx Pharmaceuticals (NRXP) Stock Jumps Over 26% After Hours: What's Behind the Surge?
      Oct 30BenzingaNRXP
      NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine
      Oct 29Yahoo FinanceNRXP
      Why Drug Companies Are Rushing to Market Ketamine Medicines
      Oct 21The New York TimesNRXP
      NRx Pharmaceuticals completes manufacturing validation for preservative-free ketamine
      Oct 19Investing.comNRXP
      NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine
      Oct 19Yahoo FinanceNRXP
      NRx Pharmaceuticals Sets 2026 Virtual Annual Meeting Date

      Tipranks Press Release.

      Oct 17The Globe and MailNRXP
      NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine

      In advance of November 10, 2026, GDUFA goal date, all requested changes were classified as “MINOR.”NRx was requested to prepare and submit labels ...

      Oct 16Business InsiderNRXP
      NRx Pharmaceuticals receives FDA letter on ketamine product
      Oct 15Investing.comNRXP
      NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine
      Oct 15Yahoo FinanceNRXP
      NRx Pharmaceuticals Lands DARPA Contract for SPARC-TMS Trial

      Tipranks Press Release.

      Oct 6The Globe and MailNRXP
      NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression

      DARPA states that the program, if successful, will fundamentally change the Standard of Care for Treatment Resistant Depression. The Military has recognized that current treatments for depression are not deployable in operational military settings.The SPARC-TMS Single Day treatment protocol, which involves the use of Robotic Neuronavigated Transcranial Magnetic Stimulation (TMS) augmented by NRx’s neuroplastic investigational drug NRX-101, is based on a recently completed randomized-controlled t

      Sep 30Yahoo FinanceNRXP
      NRX Pharmaceuticals (NRXP) Receives a Rating Update from a Top Analyst

      Detailed price information for Nrx Pharmaceuticals Inc (NRXP-Q) from The Globe and Mail including charting and trades.

      Sep 23The Globe and MailNRXP
      NRx Pharmaceuticals’ ketamine ANDA amendment reclassified
      Sep 15Investing.comNRXP
      NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine

      Abbreviated New Drug Application (ANDA) Amendment related to the drug vial for preservative-free ketamine has been reclassified from a Major Amendment to a Minor Amendment.FDA has revised the Generic Drugs User Fee Act (GDUFA) Goal Date to November 10, 2026. WILMINGTON, Del., Sept. 15, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it has received a written communi

      Sep 15Yahoo FinanceNRXP
      NRx Pharmaceuticals: Promising Ketamine Opportunity In Psychiatry (NASDAQ:NRXP)

      KETAFREE can turn NRx Pharmaceuticals’ ketamine opportunity into a commercial business, provided FDA approval leads to a successful launch. More on NRXP stock.

      Sep 14Seeking AlphaNRXP
      GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)

      Invention is based on the discovery that ALS may be caused by reactivation of Human Endogenous Retrovirus K (HERV K) Envelope protein (K Env), already coded in the “dark genome” of all people. K Env is found in the spinal fluid of more than 75% of people with ALS and has been shown to produce the neurodegenerative findings of ALS in experimental animals and human neuron cells. The patent (EP 3 570 878 B1) covers a novel monoclonal antibody (GNK-301) developed by GeNeuro and scientists at the US

      Sep 14Yahoo FinanceNRXP
      NRx Pharmaceuticals at Cantor conference: ketamine push gains momentum
      Sep 11Investing.comNRXP
      NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System

      HOPE is the first Interventional Psychiatry network to deploy Zeta Surgical's newly FDA-cleared TMS Robotic System; the HOPE clinical team is completing orientation and training at Zeta Surgical's headquarters in Boston ahead of deployment in HOPE's Florida clinicsThe Zeta TMS Robotic System's AI-driven software adjusts the TMS coil in real time with submillimeter precision, building on the Zeta TMS Navigation System HOPE implemented earlier this summerDeployment supports SPARC-TMS, NRx's trial

      Sep 11Yahoo FinanceNRXP
      NRx Pharmaceuticals to Participate in Upcoming Investor Conferences

      WILMINGTON, Del., Sept. 08, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that the management team will participate in three upcoming investor conferences in September 2026. Moody Capital Solutions 2026 Disruptive Growth & Life Sciences ConferenceCompany PresentationPresenter: Jonathan Javitt, M.D., M.P.H., Founder, Chairman and Chief Executive Officer of NRx PharmaceuticalsL

      Sep 8Yahoo FinanceNRXP
      H.C. Wainwright reiterates Buy on NRx Pharmaceuticals stock at $45
      Aug 26Investing.comNRXP
      FDA First Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies Noted for Suicidal Bipolar Depression Treatment from NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

      $NRXP Has Also Treated its First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation SystemWILMINGTON, DELAWARE - Aug. 20, 2026 - NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company developing therapeutic...

      Aug 24BarchartNRXP

      This is the newest page. Registered accounts read further back.